Demeclocycline treatment of water retention in congestive heart failure Demeclocycline has been shown to induce nephrogenic diabetes insipidus in normal subjects.' It has been used successfully for treating the syndrome of inappropriate antidiuretic hormone secretion2 3 and water retention related to liver cirrhosis.4 The findings presented here show its efficacy in cardiac oedema unresponsive to classic diuretic treatment.
Patients, methods, and results
Six patients with chronic congestive heart failure were investigated. Each patient had longstanding overt salt and water retention which had become unresponsive to low salt diet, diuretics, and digitalis treatment. Three patients had overt hyponatraemia. Except for digitalis, which was maintained at the same daily dose, all drugs were withheld throughout the study. The patients were allowed to drink water freely but dietary salt was restricted to 10-20 mmol (mEq)/day. After five days' bed rest and dietary salt restriction without any change in salt and water retention demeclocycline (1200 mg/day by mouth) was started.
One patient did not respond to treatment over nine days. The 
Comment
Demeclocycline is known to inhibit the antidiuretic hormone sensitive medullary adenylcyclase from the kidney,' thus inducing a reversible nephrogenic diabetes insipidus. The drug has been shown to be useful in treating hyponatraemia and water intoxication in patients with inappropriate antidiuretic hormone secretion,' suggesting inhibition of the tubular response to tumoral antidiuretic products.
Demeclocycline has also been successfully used to treat chronic oedema in cirrhotic patients,' inducing substantial increases iI urinary water and sodium excretion. An identical effect occurred iI our patients with chronic oedema of cardiac origin, suggesting tha the antidiuretic hormone is at least partially responsible for th4 abnormal water metabolism in liver cirrhosis and heart decompensa tion. Demeclocycline seems to be very effective in these conditions in five of our six patients treatment caused the rapid disappearanc4 of a large fluid accumulation that had not been prevented by classi diuretic treatment. Moreover, hyponatraemia was easily controllec in three patients, which suggested that demeclocycline might bi especially indicated in hyponatraemic oedematous patients.
Demeclocycline administration substantially increased urinar sodium excretion in our patients; this confirmed the natriureti4 effect of the drug, which has been noticed in cirrhotic oedematou:
patients.4 The mechanism of the induced natriuresis is unknown but an increase in urinary sodium concentration has also been showr to occur in patients with renal insufficiency under tetracycline treat ment.5
The known antianabolic effect of demeclocycline5 may partiall3 explain the rise in blood urea concentration. In all the patients studiec there was also a moderate rise in blood creatinine concentration Hypovolaemia probably does not explain the reversible impairmeni of renal function since the only patient who did not respond to DMC by water and sodium excretion also showed an increase in blooc creatinine concentration. A drug-related nephrotoxicity must there. fore be postulated. Regular monitoring of renal function is requirec during demeclocycline treatment and the drug is probably contraindicated in patients with baseline azotaemia. Nevertheless, the beneficial effects of this treatment probably outweigh its drawbacks. Changes in weight, water and sodium excretion, serum sodium, urine osmolality, and blood urea and creatinine concentrations before, during, and after demeclocycline (DMC) treatment (1200 mg/day) in five patients with congestive heart failure and oedema.
Conversion: SI to traditional units-Sodium: 1 mmol= 1 mEq. Osmolality: 1 mmol/kg H20 = 1 mosmol/kg H20. Urea: 1 mmol/l 6 mg/100 ml. Creatinine:
